HDAC4 and ovarian cancer: In general, class I HDAC1-3 are upregulated during ovarian cancer progression and correlate with a poor patient survival [154,155]; while class II HDAC4 overexpression is linked with platinum resistance as well deacetylation of STAT1 in primary ovarian cancer cells isolated from ovarian cancer patients [156].